Cover Image
市場調查報告書

肺動脈栓塞:開發中產品分析

Pulmonary Embolism - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 213109
出版日期 內容資訊 英文 37 Pages
訂單完成後即時交付
價格
Back to Top
肺動脈栓塞:開發中產品分析 Pulmonary Embolism - Pipeline Review, H2 2017
出版日期: 2017年08月16日 內容資訊: 英文 37 Pages
簡介

所謂肺動脈栓塞,是指肺內部的血管(肺動脈)突然(通常因血塊)阻塞的疾病。主要症狀是呼吸急促和胸痛、咳嗽、腿部疼痛和膨脹、過度發汗、心律的劇增和心律不整,暈眩等。主要易罹病素質,有高血壓和心血管疾病等。治療方法為抗凝固藥和血栓溶解藥等。

本報告提供全球各國治療肺動脈栓塞(肺動脈栓塞症)所用之開發中產品開發情形相關分析、提供您開發中產品的最新趨勢,及臨床實驗的各階段產品一覽,再加上主要企業簡介、主要藥物概要、最新的產業趨勢等調查。

目錄

簡介

  • 分析範圍

肺動脈栓塞概要

治療藥的開發

  • 肺動脈栓塞開發中產品:概要
  • 肺動脈栓塞開發中產品:比較分析

各企業開發中的肺動脈栓塞治療藥

大學/研究機關研究中的肺動脈栓塞治療藥

開發中產品的概要

  • 後期階段的產品
  • 初期階段的產品

肺動脈栓塞治療藥:開發中的產品一覽(各企業)

肺動脈栓塞治療藥:研究中的產品一覽(各大學/研究機關)

肺動脈栓塞治療藥的開發企業

  • Accu-Break Pharmaceuticals, Inc.
  • Dong-A Socio Holdings Co. Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Genentech, Inc.

肺動脈栓塞:治療藥的評估

  • 單劑治療藥的情況
  • 標的別
  • 各行動機制
  • 各投藥法
  • 各分子類型

藥物簡介

肺動脈栓塞治療藥:開發暫停的產品

肺動脈栓塞治療藥:開發中止的產品

肺動脈栓塞相關產品的開發的里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9611IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pulmonary Embolism - Pipeline Review, H2 2017, provides an overview of the Pulmonary Embolism (Cardiovascular) pipeline landscape.

Pulmonary embolism is the sudden blockage of a major blood vessel (artery) in the lung, usually by a blood clot. Symptoms include shortness of breath, chest pain, cough, leg pain or swelling, excessive sweating, rapid or irregular heartbeat and dizziness. Predisposing factors include High blood pressure and cardiovascular disease. Treatment includes anticoagulants and thrombolytics.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pulmonary Embolism - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Pulmonary Embolism (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pulmonary Embolism (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Pulmonary Embolism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I and Preclinical stages are 2, 1, 1 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Pulmonary Embolism (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Pulmonary Embolism (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Pulmonary Embolism (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Pulmonary Embolism (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Pulmonary Embolism (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Pulmonary Embolism (Cardiovascular)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Pulmonary Embolism (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Pulmonary Embolism (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Pulmonary Embolism - Overview
    • Pulmonary Embolism - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Pulmonary Embolism - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Pulmonary Embolism - Companies Involved in Therapeutics Development
    • Accu-Break Pharmaceuticals Inc
    • Daiichi Sankyo Company Ltd
    • Dong-A Socio Holdings Co Ltd
    • F. Hoffmann-La Roche Ltd
    • Verseon Corp
  • Pulmonary Embolism - Drug Profiles
    • DS-1040 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DS-9231 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Heparin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit Cyclooxygenase and Glycoprotein IIb/IIIa for Pulmonary Embolism and Hematological Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Thrombin for Cardiovascular Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TRX-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • warfarin potassium - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Pulmonary Embolism - Dormant Projects
  • Pulmonary Embolism - Discontinued Products
  • Pulmonary Embolism - Product Development Milestones
    • Featured News & Press Releases
      • Nov 28, 2016: Research to Be Presented at ASH Annual Meeting Shows Verseon's New Class of Anticoagulants Prevents Thrombosis While Preserving Platelet Function
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Pulmonary Embolism, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Pulmonary Embolism - Pipeline by Accu-Break Pharmaceuticals Inc, H2 2017
  • Pulmonary Embolism - Pipeline by Daiichi Sankyo Company Ltd, H2 2017
  • Pulmonary Embolism - Pipeline by Dong-A Socio Holdings Co Ltd, H2 2017
  • Pulmonary Embolism - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017
  • Pulmonary Embolism - Pipeline by Verseon Corp, H2 2017
  • Pulmonary Embolism - Dormant Projects, H2 2017
  • Pulmonary Embolism - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for Pulmonary Embolism, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products by Targets, H2 2017
  • Number of Products by Stage and Targets, H2 2017
  • Number of Products by Mechanism of Actions, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top